The safety of vedolizumab for ulcerative colitis and Crohn's disease

OBJECTIVE: Vedolizumab is a gut-selective antibody to α(4)β(7) integrin for the treatment of ulcerative colitis (UC) and Crohn's disease (CD). We report an integrated summary of the safety of vedolizumab. DESIGN: Safety data (May 2009–June 2013) from six trials of vedolizumab were integrated. A...

Descripción completa

Detalles Bibliográficos
Autores principales: Colombel, Jean-Frédéric, Sands, Bruce E, Rutgeerts, Paul, Sandborn, William, Danese, Silvio, D'Haens, Geert, Panaccione, Remo, Loftus, Edward V, Sankoh, Serap, Fox, Irving, Parikh, Asit, Milch, Catherine, Abhyankar, Brihad, Feagan, Brian G
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2017
Materias:
Inflammatory Bowel Disease
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5531223/
https://www.ncbi.nlm.nih.gov/pubmed/26893500
http://dx.doi.org/10.1136/gutjnl-2015-311079

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5531223/
https://www.ncbi.nlm.nih.gov/pubmed/26893500
http://dx.doi.org/10.1136/gutjnl-2015-311079

Ejemplares similares